GERN Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.07 |
| 52 Week High | US$5.34 |
| 52 Week Low | US$1.64 |
| Beta | 0.51 |
| 11 Month Change | 0.25% |
| 3 Month Change | -12.66% |
| 1 Year Change | 113.09% |
| 33 Year Change | 180.69% |
| 5 Year Change | 184.62% |
| Change since IPO | -47.48% |
Recent News & Updates
Geron: A Post Earnings And Funding Announcement Assessment
Nov 07Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28
Recent updates
Geron: A Post Earnings And Funding Announcement Assessment
Nov 07Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)
Aug 12Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition
Jul 31Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
May 12An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued
Dec 20Geron: A Major Catalyst For Shareholders Arrives In January - At Last
Sep 16Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?
Sep 14Geron rises on narrower-than-expected Q2 loss
Aug 12Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt
Aug 05Geron: Waiting For Godot
Jul 15Shareholder Returns
| GERN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.7% | 2.5% | 2.2% |
| 1Y | 113.1% | 16.1% | 31.6% |
Return vs Industry: GERN exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: GERN exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| GERN volatility | |
|---|---|
| GERN Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GERN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GERN's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| GERN fundamental statistics | |
|---|---|
| Market cap | US$2.46b |
| Earnings (TTM) | -US$201.19m |
| Revenue (TTM) | US$29.48m |
83.5x
P/S Ratio-12.2x
P/E RatioIs GERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GERN income statement (TTM) | |
|---|---|
| Revenue | US$29.48m |
| Cost of Revenue | US$112.38m |
| Gross Profit | -US$82.90m |
| Other Expenses | US$118.29m |
| Earnings | -US$201.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -281.22% |
| Net Profit Margin | -682.47% |
| Debt/Equity Ratio | 28.7% |
How did GERN perform over the long term?
See historical performance and comparison